Physician profile
Hesun Han
NPI 1609804020
$4,748.45
in general payments reported to CMS, 2019-2025
28 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $389 · 2021: $420 · 2022: $714 · 2023: $786 · 2024: $1,108 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675 · Education: $72.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,675.04 |
| Education | $72.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $535.55 | 2019-2023 | Krystexxa |
| Amgen INC. | $467.99 | 2019-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $437.68 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $380.44 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $375.82 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $367.29 | 2020-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $265.11 | 2022-2025 | |
| Akebia Therapeutics INC | $221.99 | 2019-2024 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $209.57 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $194.52 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $170.09 | 2019-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $166.23 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.11 | 2023-2025 | Jardiance |
| Outset Medical INC | $125.00 | 2023 | |
| Daiichi Sankyo INC. | $123.85 | 2019-2024 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $120.43 | 2021-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $86.38 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $81.08 | 2020-2025 | Acthar |
| Genzyme Corporation | $38.86 | 2019-2022 | |
| Baxter Healthcare | $38.75 | 2023 | Renal - Pd |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.93 | 2025 | |
| Alexion Pharmaceuticals, INC. | $27.68 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $27.68 | 2023 | Gattex |
| Scpharmaceuticals INC. | $25.65 | 2025 | |
| Ardelyx, INC. | $24.61 | 2025 | Ibsrela |
| Hikma Pharmaceuticals USA | $22.82 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.68 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $15.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hesun Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.